Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation
Health Technology Assessment2002Vol. 6(3), pp. 1–85
Citations Over TimeTop 16% of 2002 papers
Related Papers
- → End of Rituximab Maintenance for Low–Tumor Burden Follicular Lymphoma(2014)9 cited
- → Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?(2017)8 cited
- → Rituximab maintenance therapy in follicular lymphoma(2007)5 cited
- → Remission after Rituximab Therapy in Refractory Myasthenia Gravis(2017)2 cited
- → Rituximab for low-grade follicular lymphoma?(2014)